Baxdrostat Reduces Seated Systolic BP in Uncontrolled, Resistant Hypertension
MONDAY, Sept. 8, 2025 -- The addition of baxdrostat, an aldosterone synthase inhibitor, to background therapy yields a significant reduction in seated systolic blood pressure among patients with uncontrolled or resistant hypertension, according to a study published online Aug. 30 in the New England Journal of Medicine to coincide with the European Society of Cardiology Congress 2025, held from Aug. 29 to Sept. 1 in Madrid.
John M. Flack, M.D., from Southern Illinois University in Springfield, and colleagues conducted a phase 3 randomized trial involving patients with a seated systolic blood pressure of 140 mm Hg to less than 170 mm Hg despite receipt of stable treatment with two antihypertensive medications or three or more such medications (uncontrolled hypertension and resistant hypertension, respectively). Patients with a seated systolic blood pressure of 135 mm Hg or more after a two-week placebo run-in period were randomly assigned to receive 1 mg baxdrostat, 2 mg baxdrostat, or placebo once daily for 12 weeks (264, 266, and 264 patients, respectively).
The researchers found that the change from baseline in the least-squares mean seated systolic blood pressure at 12 weeks was −14.5, −15.7, and −5.8 mm Hg with 1 mg baxdrostat, 2 mg baxdrostat, and placebo, respectively. The estimated placebo-corrected difference was −8.7 and −9.8 mm Hg with 1 mg and 2 mg baxdrostat, respectively. Overall, 2.3, 3.0, and 0.4 percent of patients receiving 1 mg baxdrostat, 2 mg baxdrostat, and placebo, respectively, had a potassium level of more than 6.0 mm/L.
"Achieving a nearly 10-mm Hg reduction in systolic blood pressure with baxdrostat in the BaxHTN phase III trial is exciting, as this level of reduction is linked to substantially lower risk of heart attack, stroke, heart failure, and kidney disease," principal author Bryan Williams, M.D., from the University College London, said in a statement.
Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures baxdrostat and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Guidance Issued on Impact, Management of Potassium, Phosphorus in CKD
THURSDAY, Sept. 25, 2025 -- Guidance is presented for understanding the impact of potassium and phosphorus additives on people with chronic kidney disease (CKD) and managing their...
Only 36.4 Percent of U.S. Adults Had No CVD Risk Factors in Recent Years
WEDNESDAY, Sept. 24, 2025 -- During August 2021 to August 2023, only 36.4 percent of U.S. adults had no cardiovascular disease (CVD) risk factors, according to a September data...
Three Cardiometabolic Risk Factors ID'd as Having the Highest Risk for Mortality in MASLD
TUESDAY, Sept. 23, 2025 -- For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the cardiometabolic risk factors (CMRFs) of high blood pressure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.